Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity

References

• Babakhanian K, Bendayan M, Bendayan R. (2007). Localization of P-glycoprotein at the nuclear envelope of rat brain cells. Biochem Biophys Res Commun 361:301–6
   PubMed Web of Science ®Google Scholar
• Bagalkot V, Farokhzad OC, Langer R, et al. (2006). An aptamer–doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed 45:8149–52
   PubMed Web of Science ®Google Scholar
• Ballangrud ÅM, Yang W-H, Dnistrian A, et al. (1999). Growth and characterization of LNCaP prostate cancer cell spheroids. Clin Cancer Res 5:3171s–6s
   PubMed Web of Science ®Google Scholar
• Bergh J, Jönsson P-E, Glimelius B, et al. (2001). A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 40:253–81
   PubMed Web of Science ®Google Scholar
• Borowski E, Bontemps-Gracz MM, Piwkowska A. (2005). Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochimica Polonica Engl 52:609--27
   PubMed Web of Science ®Google Scholar
• Calcabrini A, Meschini S, Stringaro A, et al. (2000). Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells. Histochem Cell 32:599–606
   PubMedGoogle Scholar
• Coley HM. (2008). Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 34:378–90
   PubMed Web of Science ®Google Scholar
• Dean M, Allikmets R. (2001). Complete characterization of the human ABC gene family. J Bioenerg Biomembr 33:475–9
   PubMed Web of Science ®Google Scholar
• Duhem C, Ries F, Dicato M. (1996). What does multidrug resistance (MDR) expression mean in the clinic? Oncologist 1:151–8
   PubMedGoogle Scholar
• Farquhar MG. (1983). Intracellular membrane traffic: pathways, carriers, and sorting devices. Meth Enzymol 98:1–13
   PubMed Web of Science ®Google Scholar
• Frank M. (1993). The reticuloendothelial system and bloodstream clearance. J Lab Clin Med 122:487--8
   PubMed Web of Science ®Google Scholar
• Futaki S, Hirose H, Nakase I. (2013). Arginine-rich peptides: methods of translocation through biological membranes. Curr Pharm Des 19:2863–8
   PubMed Web of Science ®Google Scholar
• Futaki S, Suzuki T, Ohashi W, et al. (2001). Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276:5836–40
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Zhang S, et al. (2014). Study and evaluation of mechanisms of dual targeting drug delivery system with tumor microenvironment assays compared with normal assays. Acta Biomater 10:858–67
   PubMed Web of Science ®Google Scholar
• Gervasoni JE, Fields SZ, Krishna S, et al. (1991). Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res 51:4955–63
   PubMed Web of Science ®Google Scholar
• Goldberg D, Winfield D. (1972). Diagnostic accuracy of serum enzyme assays for myocardial infarction in a general hospital population. Brit Heart J 34:597--604
   PubMedGoogle Scholar
• He Q, Tang J, Qin Y. (2012). A reduction-sensitive liposome based on the cholesterol derivatization for tumor targeting. Chinese patent ZL201110197327.9
   Google Scholar
• Ishida T, Harada M, Wang XY, et al. (2005). Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release 105:305–17
   PubMed Web of Science ®Google Scholar
• Jabr-Milane LS, van Vlerken LE, Yadav S, et al. (2008). Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 34:592–602
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Alakhov VY. (2002). Pluronic® block copolymers for overcoming drug resistance in cancer. Adv Drug Deliver Rev 54:759–79
   PubMed Web of Science ®Google Scholar
• Kang KW, Chun M-K, Kim O, et al. (2010). Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine 6:210–13
   PubMed Web of Science ®Google Scholar
• Kaur V, Garg T, Rath G, et al. (2014). Therapeutic potential of nanocarrier for overcoming to P-glycoprotein. Drug Deliv 22:859–70
   Google Scholar
• Kuai R, Yuan W, Li W, et al. (2011). Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration. Mol Pharm 8:2151–61
   PubMed Web of Science ®Google Scholar
• Kuai R, Yuan W, Qin Y, et al. (2010). Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes. Mol Pharm 7:1816–26
   PubMed Web of Science ®Google Scholar
• Lippincott-Schwartz J, Yuan L, Tipper C, et al. (1991). Brefeldin A's effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic. Cell 67:601–16
   PubMed Web of Science ®Google Scholar
• Maeda T, Fujimoto K. (2006). A reduction-triggered delivery by a liposomal carrier possessing membrane-permeable ligands and a detachable coating. Colloids Surf B 49:15–21
   PubMed Web of Science ®Google Scholar
• McNeeley KM, Karathanasis E, Annapragada AV, et al. (2009). Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 30:3986–95
   PubMed Web of Science ®Google Scholar
• Milane L, Duan Z, Amiji M. (2011). Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One 6:e24075
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. (2006). Drug penetration in solid tumours. Nature Rev Cancer 6:583–92
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229
   PubMed Web of Science ®Google Scholar
• Molinari A, Cianfriglia M, Meschini S, et al. (1994). P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells. Int J Cancer 59:789–95
   PubMed Web of Science ®Google Scholar
• Ozer JS, Chetty R, Kenna G, et al. (2010). Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regul Toxicol Pharm 56:237–46
   PubMed Web of Science ®Google Scholar
• Patel NR, Rathi A, Mongayt D, et al. (2011). Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm 416:296–9
   PubMed Web of Science ®Google Scholar
• Pennock GD, Dalton WS, Roeske WR, et al. (1991). Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83:105–10
   PubMed Web of Science ®Google Scholar
• Qin Y, Chen H, Yuan W, et al. (2011). Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm 419:85–95
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Hafström L, Nygren P, et al. (2001). A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40:282–308
   PubMed Web of Science ®Google Scholar
• Rivera E. (2010). Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes. Am J Clin Oncol 33:176–85
   PubMed Web of Science ®Google Scholar
• Sharma G, Modgil A, Layek B, et al. (2013). Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection. J Control Rel 167:1–10
   PubMed Web of Science ®Google Scholar
• Shi Z, Tiwari AK, Patel AS, et al. (2011). Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res 71:3735–8
   PubMed Web of Science ®Google Scholar
• Sobel BE, Shell WE. (1972). Serum enzyme determinations in the diagnosis and assessment of myocardial infarction. Circulation 45:471–82
   PubMed Web of Science ®Google Scholar
• Sun H, Meng F, Cheng R, et al. (2013). Reduction-sensitive degradable micellar nanoparticles as smart and intuitive delivery systems for cancer chemotherapy. Drug Deliv 10:1109–12
   Web of Science ®Google Scholar
• Szaflarski W, Sujka-Kordowska P, Januchowski R, et al. (2013). Nuclear localization of P-glycoprotein is responsible for protection of the nucleus from doxorubicin in the resistant LoVo cell line. Biomed Pharmacother 67:497–502
   PubMed Web of Science ®Google Scholar
• Tang J, Fu H, Kuang Q, et al. (2014). Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery. J Drug Target 22:313–26
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci 84:7735–8
   PubMed Web of Science ®Google Scholar
• Thierry A, Rahman A, Dritschilo A. (1993). Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun 190:952–60
   PubMed Web of Science ®Google Scholar
• Torchilin V. (2013). Membrane barriers for bringing drugs inside cells and inside cell organelles. J Membra Sci Technol 3:e114
   Google Scholar
• Tseng Y-C, Mozumdar S, Huang L. (2009). Lipid-based systemic delivery of siRNA. Adv Drug Deliver Rev 61:721–31
   PubMed Web of Science ®Google Scholar
• Tsukioka Y, Matsumura Y, Hamaguchi T, et al. (2002). Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil). Cancer Sci 93:1145–53
   Google Scholar
• Wang F, Zhang D, Zhang Q, et al. (2011). Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multi-drug resistance. Biomaterials 32:9444–56
   PubMed Web of Science ®Google Scholar
• Wang J, Sun J, Chen Q, et al. (2012). Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Biomaterials 33:6877–88
   PubMed Web of Science ®Google Scholar
• Wang L, Liu Y, Li W, et al. (2010). Selective targeting of gold nanorods at the mitochondria of cancer cells: implications for cancer therapy. Nano Lett 11:772–80
   PubMed Web of Science ®Google Scholar
• Wang X, Zhen X, Wang J, et al. (2013). Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles. Biomaterials 34:4667–79
   PubMed Web of Science ®Google Scholar
• Wender PA, Galliher WC, Goun EA, et al. (2008). The design of guanidinium-rich transporters and their internalization mechanisms. Adv Drug Deliv Rev 60:452–72
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, et al. (2006). A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 317:1372–81
   PubMed Web of Science ®Google Scholar
• Wu J, Lu Y, Lee A, et al. (2007). Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 10:350–7
   PubMed Web of Science ®Google Scholar
• Xin H, Sha X, Jiang X, et al. (2012). Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 33:8167–76
   PubMed Web of Science ®Google Scholar
• Yang X-Z, Dou S, Wang Y-C, et al. (2012). Single-step assembly of cationic lipid–polymer hybrid nanoparticles for systemic delivery of siRNA. ACS Nano 6:4955–65
   PubMed Web of Science ®Google Scholar
• Yoshimatsu K, Kuhara K, Itagaki H, et al. (2008). Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer. Anticancer Res 28:373–8
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang H, Ma Z, et al. (2014). Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns. Drug Deliv 10:1691–702
   Google Scholar
• Zhu L, Torchilin VP. (2013). Stimulus-responsive nanopreparations for tumor targeting. Integr Biol 5:96–107
   PubMed Web of Science ®Google Scholar